Immunotherapy in melanoma WC

CE

Navigating Modern Immunotherapeutic Approaches for Melanoma: Considerations for Oncology Pharmacists

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 13, 2024

Expiration: November 12, 2025

Colleen McCabe
Colleen McCabe, PharmD, BCOP
Jordan McPherson
Jordan McPherson, PharmD, MS, BCOP

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following is true regarding efficacy of adjuvant anti‒PD-1 monotherapy (nivolumab or pembrolizumab) in stage IIB/C melanoma?

2.

What is the most appropriate therapy for an otherwise healthy asymptomatic 58-yr-old patient with newly diagnosed stage IV BRAF V600E–mutant melanoma with no brain metastases and the goal of maximizing progression-free survival?

3.

Patient Case



  • HN is a 34-yr-old male with metastatic melanoma on cycle 7 of nivolumab + ipilimumab treatment

  • He presents with severe fatigue, headaches, and light sensitivity

  • 8 AM endocrine labs show low cortisol, ACTH, TSH; free T4 is also low

  • HN is diagnosed with hypophysitis

Which of the following medications would be the most appropriate initial intervention for this patient’s hypophysitis?